Send me real-time posts from this site at my email

William Blair Thinks Poseida Therapeutics’ Stock is Going to Recover

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Poseida Therapeutics (PSTXResearch Report). The company's shares closed last Tuesday at $6.49, close to its 52-week low of $6.38.

According to, Prasad is a 4-star analyst with an average return of 6.2% and a 42.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Poseida Therapeutics is a Strong Buy with an average price target of $28.50.

See today’s best-performing stocks on TipRanks >> Based on Poseida Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $45.71 million. In comparison, last year the company had a GAAP net loss of $30.43 million. Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PSTX in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Read More on PSTX:

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue